Systemic lupus erythematosus in a multiethnic US cohort XLIII. The significance of thrombocytopenia as a prognostic factor

Arthritis and Rheumatism

Volumn 56, Issue 2, 2007, Pages 614-621

  Fernández, Mónica ^a   Alarcón, Graciela S ^a   Apte, Mandar ^a   Andrade, Rosa M ^a   Vilá, Luis M ^b   Reveille, John D ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ETHNIC GROUP; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UNITED STATES;

ADULT; AFRICAN AMERICANS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; UNITED STATES;

EID: 33847015601     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22376     Document Type: Article

References (41)

1. Kaplan C, Champeix P, Blanchard D, Muller JY, Cartron JP. Platelet antibodies in systemic lupus erythematosus. Br J Haematol 1987;67:89-93.
2. Pujol M, Ribera A, Vilardell M, Ordi J, Feliu E. High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus. Br J Haematol 1995;89:137-41.
3. Ziakas PD, Routsias JG, Giannouli S, Tasidou A, Tzioufas AG, Voulgarelis M. Suspects in the tale of lupus-associated thrombocytopenia. Clin Exp Immunol 2006;145:71-80.
4. Cervera R. Khamashta MA. Font J, Sebastiani GD, Gil A, Lavilla P, et al. for the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus ery-thematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999;78:167-75.
5. Rabinowitz Y, Dameshek W. Systemic lupus erythematosus after "idiopathic" thrombocytopenic purpura: a review. Ann Intern Med 1960;52:1-28.
6. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
7. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156:1337-44.
8. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
9. Ward MM, Pajevic S, Dreyfuss J, Malley JD. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum 2006;55:74-80.
10. Alzeer AH, Al Arfaj A, Basha SJ, Alballa S, Al Wakeel J, Al Arfaj H, et al. Outcome of patients with systemic lupus erythematosus in intensive care unit. Lupus 2004;13:537-42.
11. Ziakas PD, Dafni UG, Giannouli S, Tzioufas AG, Voulgarelis M. Thrombocytopaenia in lupus as a marker of adverse outcome-seeking Ariadne's thread. Rheumatology (Oxford) 2006;45:1261-5.
12. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197-209.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
15. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J. et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
16. US Bureau of the Census. Current population reports: Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington, DC: US Bureau of the Census, Housing and Household Economic Statistics Division; 1995.
17. Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, et al. Genetic linkage and association of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002;46:2132-40.
18. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
19. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
20. Aarden LA, De Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann NY Acad Sci 1975;254:505-15.
21. Hamilton RG, Harley JB, Bias WB, Roebber M, Reichlin M. Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus: correlation of HLA-DR/DQ spec-ificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505.
22. Harris EN. Special report: the Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94:476-84.
23. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
24. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) 2003;42:230-4.
25. Ziakas PD, Giannouii S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366-9.
26. Alger M, Alarcon-Segovia D, Rivero SJ. Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus. J Rheumatol 1977;4:351-7.
27. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
28. Uribe AG, McGwin G Jr, Reveille JD, Alarcon GS. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities: Nature vs. Nurture) cohort? Where are we heading? Autoimmun Rev 2004;3:321-9.
29. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976;55:323-38.
30. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000;108:198-204.
31. Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997;24:867-70.
32. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 1985;59:227-30.
33. Whittingham S. Autoantibodies in systemic lupus erythematosus. Ann Acad Med Singapore 1988;17:195-200.
34. Christian CL. Hepatitis B virus (HBV) and systemic vasculitis. Clin Exp Rheumatol 1991;9:1-2.
35. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
36. Martinez-Cordero E, Vega-Avila E, Negrete-Garcia MC, Zamudio-Cortes P, Aguilar-Frausto I. Thrombocytopenic purpura and hemolytic anemia in children with generalized lupus erythematosus. Bol Med Hosp Infant Mex 1991;48:463-8. In Spanish.
37. Chien JW, Lin CY, Yang LY. Correlation between anti-Ro/La titers and clinical findings of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:283-91.
38. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003-10.
39. Pisetsky DS, Gilkeson G, St. Clair EW. Systemic lupus erythematosus: diagnosis and treatment. Med Clin North Am 1997;81:113-28.
40. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum 1983;26:1181-6.
41. Urowitz MB. SLE subsets-divide and conquer. J Rheumatol 1977;4:332-3.